spot_img
Monday, August 15, 2022
More
    HomeHealthFDA halts study of Sarepta treatment for Duchenne muscular dystrophy

    FDA halts study of Sarepta treatment for Duchenne muscular dystrophy

    -



    Sarepta Therapeutics mentioned Thursday that it has quickly stopped a medical trial of its second-generation drugs for sufferers with a sure kind of Duchenne muscular dystrophy resulting from a severe security incident reported by a affected person.

    The Meals and Drug Administration positioned a medical maintain on the Sarepta drug, known as SRP-5051, after a affected person within the research skilled a “severe” lower in blood-based magnesium, a situation often called hypomagnesemia.

    Unlock this text by subscribing to STAT+ and revel in your first 30 days free!

    GET STARTED





    Source link

    Related articles

    Stay Connected

    0FansLike
    0FollowersFollow
    3,437FollowersFollow
    0SubscribersSubscribe
    spot_img

    Latest posts